Hello! I'm Eric Stahre, General Manager for Genomics and Molecular Imaging at GE Medical Systems. Welcome to the 48th annual Society of Nuclear Medicine show.
Molecular imaging represents the cutting-edge of medical technology. Today, many physicians can be frustrated because current detection and treatment of disease can be late stage ... later than they would prefer and with limited treatment options.
GE Medical Systems is teaming up with leaders in the area of novel contrast agents and proteomics to bring physicians new means of diagnosing disease and assessing risk before symptoms appear and without unnecessary exploratory procedures. GE Medical System's non-invasive molecular imaging methods -- such as (PET) combined with (CT) or (MRI) combined with novel imaging agents -- are being developed to detect pre-symptomatic disease. At the same time, genetic- and protein-based analysis systems are being developed to aid in defining and identifying patient populations at high risk for specific diseases. GE Medical Systems is combining our molecular imaging with applied genomics research to help detect and assess risk levels for diseases such as breast and prostate cancer.
The University of Texas M.D. Anderson Cancer Center in Houston will pilot the initial multi-disciplinary research using these combined technologies. Down the road, linking imaging information with genetic and protein data will have the potential to help cancer professionals diagnose disease earlier, individualize treatment and confirm the effectiveness of treatment - nothing short of a revolution in health care delivery.
By using our site or downloading materials from the site, you agree to our Privacy Policy and Terms of Use. Click above to review those policies. If you do not agree, do not use the site or download any materials from it.
